For Researchers
The Oxford GI Biobank is primarily intended to provide validated biological samples in association with clinical data to support research into gastroenterological disease. The Biobank is strongly supported by the Translational Gastroenterology & Liver Unit (TGLU) that integrates the ORHT clinical department of Gastroenterology with the University of Oxford Nuffield Department of Medicine, Division of Experimental Medicine. Furthermore, by integrating the operation of the Biobank with the wider Oxford Radcliffe Biobank, samples will also be available to other researchers in the hospital, University, and more widely.
The major focus of research in the TGLU currently is inflammatory bowel disease, colorectal cancer, and innovative diagnostic and therapeutic approaches to these major diseases. Many samples in the Biobank will be derived from patients with IBD or with bowel cancer, and other samples, for instance from patients with irritable bowel syndrome, could form important control groups for comparison.
Typical uses of samples in the Biobank will include analysis of immunological and chemical changes associated with disease, characterisation of changes in cells and tissues with inflammation, and correlation of genetic background with disease activity.
Application Process for Project Proposals
Please download and complete the TGLU Sub-Project Application Form and save in the suggested name format NAME_SURNAME_DATE_TGLURequestForm.
Click here TGLU Sub-Project Application Form to download a copy.
The form must be completely filled in with as much detail as possible to be considered. Request forms are reviewed each month at the TGLU Internal Committee meeting which is usually held on the third Thursday of the month.
Once a proposal has been submitted, it will be reviewed by the TGLU Internal Committee and a decision/ comments will be sent back to the PI and/or the person who submitted the form.
To amend any existing sub-projects, please submit your form with your existing project proposal and clearly mark your amendments in RED lettering.
A formal approval letter will be sent to the PI of the project, as well as a conduct form. Projects may only start collecting samples under our ethics once they have received approval either by email or by formal approval letter.
*PLEASE NOTE DEADLINE FOR SUBMISSION*
The application submission deadline is up to (not including) ONE week before the third Thursday of every month. Applications received after this will be automatically transferred to the next month's meeting.
The Lead Applicant or contact person will be required to attend this review meeting which is held via Teams on the third Thursday of the month.
RECENT APPLICATIONS
PI Name | Title | Contact | Type | Review Date |
Paul Klenerman | Characterizing immune responses before, during and after functional cure of hepatitis B in persons with HIV | paul.klenerman@ndm.ox.ac.uk | New | 6 Mar 2025 |
Alissa Walsh | The ELEPHANTS Study - Etrasimod Longitudinal E-Proms to monitor Holistic outcomes ANd Therapy Sequencing | lawrence.matini@ndm.ox.ac.uk | New | 6 Mar 2025 |
Alissa Walsh | To assess the validity of the VDZ-CDST when used to categorise clinical remission and assess changes in patient reported outcomes at 52 weeks following vedolizumab initiation in patients with moderate to severe Crohn’s Disease | lawrence.matini@ndm.ox.ac.uk | New | 6 Mar 2025 |
Simon Leedham | Go-Precise_CRC | Elizabeth.mann@oncology.ox.ac.uk | New | 6 Mar 2025 |
Prof Fadi Issa | Dissecting common immunopathological pathways in IBD and intestinal transplantation via advanced spatial omics | Charlotte.yates@ouh.nhs.uk | New | 6 Mar 2025 |
Simon Leedham | Collection and morpho-molecular characterization of gastrointestinal neoplasia | simon.leedham@well.ox.ac.uk | Amendment | 16 Jan 2025 |
Katherine Bull | The role of mucosal B cells in IgA nephropathy | katherine.bull@ndm.ox.ac.uk | New | 16 Jan 2025 |
Shazia Irshad | Effect of Mesenchymal Stem Cell (MSC)-derived proteins (CEXCI™) on intestinal stem cells | shazia.irshad@ndcls.ox.ac.uk | New | 21 Nov 2024 |
Fiona Powrie | Characterization of the cellular and molecular role of NLRP3 in IL-1β-driven intestinal bowel disease pathotype | fiona.powrie@kennedy.ox.ac.uk | New | 21 Nov 2024 |
David Church | LynchVax study | david.church@well.ox.ac.uk | Amendment | 17 Oct 2024 |
Paul Klenerman | Analysis of human colon polyps and colorectal cancer and healthy tissue; Assessment of the immunogenicity of human lncRNA- and Retained Intron-derived peptides | paul.klenerman@medawar.ox.ac.uk | Amendment | 17 Oct 2024 |